Participant visits complete in phase 2b trial of CLS-AX for wet AMD - Healio
Clearside Biomedical completes final participant visit in phase 2b ODYSSEY trial of CLS-AX for wet AMD, aiming to provide a safer treatment option with reduced burden. Topline results expected in early October.
Reference News
Participant visits complete in phase 2b trial of CLS-AX for wet AMD - Healio
Clearside Biomedical completes final participant visit in phase 2b ODYSSEY trial of CLS-AX for wet AMD, aiming to provide a safer treatment option with reduced burden. Topline results expected in early October.
Clearside Biomedical complete final participant visit in ODYSSEY phase 2b trial
Clearside Biomedical has completed the final participant visit in the ODYSSEY Phase 2b clinical trial of CLS-AX for wet AMD. The database will be cleaned, verified, locked, and unblinded data analyzed. Topline results expected during the week of October 7, 2024.